

Award Number: W81XWH-16-1-0289

TITLE: Cotargeting the lncRNA-PIP3 Interaction and AKT/PI3K Signaling Axis: A Novel Paradigm for Treating Triple-Negative Breast Cancer

PRINCIPAL INVESTIGATOR: Dr. Liuqing Yang

CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center
Houston, TX 77030

REPORT DATE: October 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2017		2. REPORT TYPE Annual		3. DATES COVERED 15 Sep 2016 - 14 Sep 2017	
4. TITLE AND SUBTITLE Cotargeting the lncRNA-PIP3 Interaction and AKT/PI3K Signaling Axis: A Novel Paradigm for Treating Triple-Negative Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-16-1-0289	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Liuqing Yang E-Mail: lyang7@mdanderson.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) UNIVERSITY OF TEXAS M D ANDERSON CANCER HOUSTON TX 77030-0417				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Patients with triple-negative breast cancer (TNBC) have a high incidence of early relapse and metastasis; currently, chemotherapy and targeted therapies are the main treatment modalities for TNBC, but one-third of patients develop recurrence and drug resistance within 3 years of therapy. Recently, we have discovered that LINK-A (Lipid-Interacting Noncoding RNA for Kinase Activation), a breast cancer-upregulated lncRNA, interacts with PtdIns (3,4,5)P3. In vitro and in vivo experiments demonstrated that LINK-A is critical for breast cancer cell invasiveness and metastasis via its functional role in regulating the PI3K-AKT signaling pathway. Importantly, the pan-cancer analysis of LINK-A expression in TCGA reveals strong correlation with TNBC and its potential for metastasis. One important goal of the proposed study would be to establish LINK-A as a novel prognostic biomarker that can reliably stratify patients with TNBC according to clinical outcomes. With the aim to work on "precision medicine", we propose to investigate a novel lncRNA-dependent noncanonical PI3K-AKT pathway underlying the metastatic progression of TNBC. Therefore, combinations of PI3K-AKT pathway inhibitors with a LNA-based lncRNA targeting strategy tested in this application may deliver maximum efficacy in treating breast cancer metastasis.					
15. SUBJECT TERMS TNBC, Long non-coding RNA, PIP3, AKT, Phosphorylation, Locked Nucleic Acids, LNA, AKT inhibitor, Tumorigenesis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 8	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	6
5. Changes/Problems.....	7
6. Products.....	7
7. Participants & Other Collaborating Organization.....	8
8. Special Reporting Requirements.....	8
9. Appendices.....	8

INTRODUCTION

TNBC patients have a high incidence of early relapse and metastasis; currently, chemotherapy and targeted therapies (*e.g.* PI3K-AKT inhibition) are the main treatment modalities for TNBC, but one-third of patients develop recurrence and drug resistance within 3 years of therapy. Despite the critical need, the molecular basis for recurrence and drug resistance remains poorly understood. Recently, we have discovered that *LINK-A*, a breast cancer-upregulated lncRNA, interacts with PIP₃. *In vitro* and *in vivo* experiments demonstrated that *LINK-A* is critical for breast cancer cell invasiveness and metastasis via its functional role in regulating the PI3K-AKT signaling pathway. Surprisingly, the pan-cancer analysis of *LINK-A* expression in TCGA reveals strong correlation with TNBC and its potential for metastasis. One important goal of the study is to identify *LINK-A* as a novel prognostic biomarker that can reliably stratify patients with TNBC according to clinical outcomes. With the aim of contributing to “precision medicine”, a key priority area highlighted by the Department of Defense, Breast Cancer Research Program overarching challenges, we propose to investigate a novel lncRNA-dependent non-canonical PI3K-AKT pathway underlying the metastatic progression of TNBC by using new technologies including RNAScope®, high-throughput sequencing, *in vivo*-grade locked nucleic acids (LNAs), and orthotopic xenograft models of human breast cancer metastasis. Therefore, combinations of PI3K-AKT pathway inhibitors with an LNA-based lncRNA targeting strategy tested in this application may deliver maximum efficacy in TNBC.

KEY WORDS

TNBC, Long non-coding RNA, PIP₃, AKT, Phosphorylation, Locked Nucleic Acids, LNA, AKT inhibitor, Tumorigenesis

ACCOMPLISHMENTS

Major goals of the project – *Our central hypothesis is that LINK-A functions to regulate the WPI3K-AKT signaling pathway via its interaction with PIP₃ in TNBC cells and that this mechanism may impact the efficacy of PI3K-AKT inhibition.* **Due to the extended evaluation and approval period regarding our animal protocol and human subjects, the grant was not set up until September 15, 2017, which is 12 months later than the proposed start date. During this period of time (09/15/2016-9/14/2017), we have established multiple collaborations nationwide, collected breast cancer tissues, established stable cell lines based on collaboration and generated a transgenic mouse model with support from the PI’s start-up funds. The research accomplishments are described under each major task of the proposed research work.**

Major Task 1: Characterization of interaction between PIP₃, LINK-A and AKT. We plan to characterize the interaction between PIP₃, *LINK-A*, and AKT *in vitro* and *in vivo*. We will also perform functional rescue experiments to demonstrate that *LINK-A*-PIP₃ interaction is required

for AKT activation and downstream cellular activities. To facilitate research investigating the functional role of *LINK-A* in cells, we have genetically edited the *LINK-A* gene into breast cancer cell lines, which will provide a reliable, reproducible, and convenient system. Gene Editing/Cellular Model Core Facility at MD Anderson has generated a genomic deletion of *LINK-A* using CRISPR/Cas9 technology based on collaboration. The single colonies derived from MDA-MB-231 cells have undergone genomic deletions of the 36 nucleotides that are required for PIP₃ binding (referred to as *LINK-A*^{ΔPIP₃}) (**Figure 1**).




Figure 1. Generation of *LINK-A* deletion mutant using CRISPR/Cas9 technology. **A**, Illustration of genomic deletion region of *LINK-A* (Chr1: 238644075-238644134) using two sgRNA as shown. **B**, DNA agarose gel detection of deletion of genomic DNA in MDA-MB-231 cells. **C**, Sanger sequencing of clone #3 indicating 36 nucleotides deletion.

To understand how *LINK-A* associates with AKT and facilitates AKT activation and the association between AKT and PIP₃, we have consulted Lei Zheng, Ph.D., Associate Professor of the University of Texas, School of Medicine, regarding the 3 dimensional structure of the AKT PH domain and computational modeling of the potential *LINK-A*-AKT-PIP₃ interaction. With his insight and advice, we were better able to understand that *LINK-A* may associate with loop 1 and loop 2 of the AKT PH domain. Crystallographic analysis indicated that the AKT PH domain harbors three variable loops (referred to as L1: aa. 16-21; L2: aa. 40-52; L3: aa. 80-81) (**Figure 2**). The phospho-groups of IP₄ form hydrogen bonds with Lys14 and Arg23, which flank L1. We hypothesize that the formation of the *LINK-A*-PIP₃-AKT complex may cause a conformational change of the AKT PH domain, which can be studied by limited proteolysis (**Figure 2**). This information will facilitate the understanding of the molecular mechanisms of *LINK-A*-dependent AKT activation.




Figure 2. Graphic illustration of *LINK-A*-AKT-PIP₃ interaction. **(A)** In the absence of *LINK-A*, Loop 2 of the AKT-PH domain is free. **(B)** In the presence of *LINK-A*, Loop 2 of the AKT PH domain may be subject to conformational change for enhanced AKT-PIP₃ interaction.

What opportunities for training and professional development has the project provided?

In the process of establishing and arranging all of the necessary collaborative efforts that are essential for the project, the PI is being connected with a diverse group of experts across the nation. Additionally, the acquired tissues broaden the tools available for future research efforts in the PI's laboratory. Although a postdoctoral fellow has yet to be named, there are an abundance of resources that foster professional development throughout the institution of MD Anderson Cancer Center and the Texas Medical Center in Houston. The postdoctoral fellow will be mentored in the research techniques and methods frequently utilized in the lab and encouraged to attend the various seminars and conferences that are held by research powerhouses in the area.

How were the results disseminated to communities of interest?

The PI was awarded the Wilson S. Stone Memorial Award by MD Anderson Cancer Center, celebrating the PI's excellence in conducting research that promotes the biomedical sciences. In accepting this award, the PI presented his research focus on noncoding RNA and cancer to the broader institutional community of students, fellows, nurses, physicians, and scientists. Also, we have been maintaining close communication with our four advocates, Furjen Deng, Susan Rafte, Bree Sandlin, and Anne Meyn, as they relay our work to their respective advocacy groups.

What do you plan to do during the next reporting period to accomplish the goals?

We will strictly adhere to the statement of work to complete all outlined tasks by the three years, although the timeline will be shifted back by one year. Thus, we plan to accomplish all goals that have been proposed for the first year.

IMPACT

What was the impact on the development of the principle disciplines of the project?

In continued efforts to direct all of the collaborative efforts that had been proposed, the PI has been able to grow his network of partner scientists in their respective fields. Additionally, the PI is establishing an impressive array of tissues that can be used as a comprehensive tool in studying various cancer types.

The proposed studies will dissect the underlying mechanisms through which lncRNAs promote tumorigenesis *in vivo*, which is a new direction for the PI. The proposed research work would serve as preliminary data for PI's next grant application.

As supported by the Breakthrough Award, the PI is being shaped into a leader in the fields of lncRNA and breast cancer research, as recognized by the Wilson S. Stone Memorial Award for research in the biomedical sciences. The PI's goal is to continue to serve as a leader within the breast cancer community; build a breast cancer noncoding RNA research/education program for junior investigators; and proactively guide breast cancer science and its dissemination.

What was the impact on other disciplines?

Our research will reveal the fundamental contribution of noncoding RNAs to various disease states, broadening interest in noncoding RNA involvement in various disease processes.

What was the impact on technology transfer?

We will provide the *LINK-A* Δ PIP3 stable cell line and pertinent *LINK-A* transgenic animal models to laboratories that are interested in further investigating this topic, after we conclude our research and publish our findings.

What was the impact on society beyond science and technology?

Therapeutic options for TNBC patients have been limited due to the interwoven signaling pathways that complicate the development of targeted therapies for TNBC. The proposed study will dissect the molecular mechanisms of lncRNA-dependent resistance to AKT inhibitors, which will highlight their clinical potential as diagnostic indicators, stratification markers, and therapeutic targets. Clinically, the lncRNA-directed targeted therapy using LNAs could serve as a promising strategy to improve outcomes for TNBC patients. This proposal will impact the field of breast cancer research by elucidating genetic evidence for the contribution of lncRNAs as oncogenes that promote breast cancer initiation and progression. Successful completion of this research will contribute to pioneering efforts to develop and mature the field of personalized medicine, specifically with regards to LNAs against TNBC relevant lncRNAs.

CHANGES/PROBLEMS:**Actual or anticipated problems or delays and actions or plan to resolve them**

We experienced about a year long delay in the start date of this grant proposal in addressing sensitive matters related to the inclusion of human subjects and animal research. Correspondence between a numbers of different parties has delayed the process more than anticipated. All concerns have been addressed and the project will officially begin on September 15, 2017.

PRODUCT**Publications, conference papers, and presentations**

Publication: We expect to publish high-impact publications at the end of the grant period.

Invited Presentations:

2016 Wilson S. Stone Award presentation “LncRNA Wire Up Cancer Signaling”, "Cancer Evolution: Mechanisms of Vulnerability and Resistance", MD Anderson, Houston, TX

PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name:	<i>Liuqing Yang</i>
Project Role:	<i>PI</i>
Researcher Identifier (e.g. ORCID ID):	<i>0000-0002-6518-474X</i>
Nearest person month worked:	<i>0</i>
Contribution to Project:	<i>Based on collaboration, PI established stable cell line to deplete PIP3 binding motif of LINK-A</i>
Funding Support:	<i>Startup funds of PI</i>

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

No

What other organizations were involved as partners?

Not applicable

SPECIAL REPORTING REQUIREMENTS

Not applicable

APPENDICES

Not applicable